Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Procter & Gamble

  • News

Executive Summary

Restructuring program will not disrupt prescription drug developments, company CEO Durk Jager says. P&G is on track for approvals of the anti-arrhythmia drug Stedicor (azimilide) within 12 months and an osteoporosis supplement for Actonel (risedronate) within nine months. P&G plans to establish 11 global business units to improve innovation and speed of commercialization. Restructuring will include lay offs of 15,000 employees worldwide, approximately 13.6% of P&G's 110,000-person workforce

Table

View full table

Tags:
Latest Headlines

Wegovy's Medicare Part D Prospects: Four Million Lives And Counting?

ICER Debuts Clinical Trial Diversity Assessment Framework

US FDA Wants Advice About Advisory Committees: Try Having Some?

Shionogi: Other Countries Must Follow UK’s Lead On Antimicrobial Incentives

See All
UsernamePublicRestriction

Register

PS034342

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By